![Dan Kirby](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 611 295 $ al 30/06/2026
Dan Kirby currently works at Iovance Biotherapeutics, Inc., as Chief Commercial Officer from 2025.
Mr. Kirby also formerly worked at Bristol Myers Squibb Co., as Vice President & Head-US Cell in 2018, Omeros Corp., as Chief Commercial Officer from 2018 to 2020, and Orca Biosystems, Inc., as Chief Commercial Officer.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 11/05/2026 | 146.946 ( 0,03 % ) | 611 295 $ | 30/06/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. | Corporate Officer/Principal | 10/02/2025 |
| Empresas | Cargo | Fin |
|---|---|---|
| OMEROS CORPORATION | Corporate Officer/Principal | 01/01/2020 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/09/2018 |
Orca Biosystems, Inc.
 Orca Biosystems, Inc. BiotechnologyHealth Technology Develops allogeneic T-cell immunotherapies for the treatment of blood cancers | Corporate Officer/Principal | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Omeros Corp.
 Omeros Corp. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes small-molecule & protein therapeutics | Health Technology |
Iovance Biotherapeutics, Inc.
 Iovance Biotherapeutics, Inc. BiotechnologyHealth Technology Develops biotechnological products for the treatment of cancer | Health Technology |
Orca Biosystems, Inc.
Orca Biosystems, Inc. BiotechnologyHealth Technology Develops allogeneic T-cell immunotherapies for the treatment of blood cancers | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
